Q Med Laboratory, LLC

Q Med Laboratory, LLC was paid $443K by Medicaid between Jan 2018 and Nov 2024, across 79 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 16% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#94 of 436

Median peer was paid$17K

This provider vs. median26×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	4,117	$189.88
2019	7,334	$2K
2020	39,576	$137K
2021	40,991	$104K
2022	38,437	$112K
2023	31,878	$65K
2024incomplete	17,933	$22K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	16%	3,932	1,933	$72K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	9.0%	2,281	1,482	$40K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	7.6%	7,811	6,698	$33K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	6.8%	516	228	$30K
80061	Lipid panel	4.4%	9,837	8,575	$19K
80050	General health panel	4.3%	1,725	1,553	$19K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	3.7%	1,983	1,192	$17K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3.3%	1,275	1,055	$15K
84443	Thyroid stimulating hormone (TSH)	3.1%	9,870	8,688	$14K
80053	Comprehensive metabolic panel	3.0%	12,863	10,548	$13K
83036	Hemoglobin; glycosylated (A1C)	2.9%	9,434	8,134	$13K
87505		2.6%	1,301	989	$11K

67 more codes

G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	2.5%	2,769	$11K
86328		2.5%	1,410	$11K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.4%	1,254	$11K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.2%	12,753	$10K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	2.0%	1,446	$9K
82607		1.8%	3,564	$8K
87500		1.6%	1,859	$7K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.4%	502	$6K
87640		1.3%	1,855	$6K
82652		1.3%	1,317	$6K
87652		1.2%	1,355	$5K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	1.0%	346	$4K
83721		<1%	5,532	$4K
86769		<1%	687	$4K
84439		<1%	3,650	$4K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	349	$3K
87641		<1%	558	$3K
87653		<1%	535	$3K
87481		<1%	532	$3K
82746		<1%	1,367	$3K
81000		<1%	5,308	$2K
82575		<1%	2,139	$2K
86413		<1%	181	$2K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	5,010	$2K
82043		<1%	2,472	$1K
83540		<1%	1,116	$1K
86318		<1%	308	$1K
83722		<1%	368	$1K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	180	$1K
86408		<1%	181	$1K
87088		<1%	1,198	$1K
84481		<1%	402	$1K
84153		<1%	574	$967.89
83735		<1%	842	$877.98
87301		<1%	389	$855.03
83970		<1%	213	$569.02
82570		<1%	1,590	$495.43
82140		<1%	105	$455.15
80048	Basic metabolic panel (calcium, ionized)	<1%	553	$404.33
85651		<1%	513	$370.38
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	102	$360.92
86140		<1%	366	$337.43
0223U		<1%	1,801	$332.60
84100		<1%	320	$319.33
87563		<1%	72	$257.07
81007		<1%	55	$257.04
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	13	$245.40
83550		<1%	305	$238.60
99000		<1%	220	$215.46
80076		<1%	295	$163.35
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	102	$152.71
85610		<1%	193	$147.30
84550		<1%	366	$127.34
81001		<1%	172	$86.36
84480		<1%	179	$72.49
85007		<1%	855	$49.81
0224U		<1%	1,198	$42.13
82550		<1%	74	$40.27
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	17,370	$27.85
80051		<1%	19	$14.86
36415	Collection of venous blood by venipuncture	<1%	16,317	$12.34
87086	Culture, bacterial; quantitative colony count, urine	<1%	34	$3.53
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	2,832	$0.10
99001		0%	170	$0.00
99072		0%	1,200	$0.00
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	0%	5,485	$0.00
0226U		0%	41	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialOMAN, SUSANA (PRESIDENT)